This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
TAWBI, HUSSEIN
| Item Type | Name |
|
Academic Article
|
Immune Checkpoint Inhibitor Therapy in a Liver Transplant Recipient With Melanoma.
|
|
Academic Article
|
Targeted Therapies in Cancer - Fourth International Congress. Epidermal growth factor receptor blockade and immune modulation.
|
|
Academic Article
|
Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma.
|
|
Academic Article
|
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.
|
|
Academic Article
|
Reply to A. Shinde et al.
|
|
Concept
|
Antibodies, Monoclonal, Humanized
|
|
Academic Article
|
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients.
|
|
Academic Article
|
A promising start for checkpoint inhibitors in childhood malignancies.
|
|
Academic Article
|
Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab.
|
|
Academic Article
|
B cells are associated with survival and immunotherapy response in sarcoma.
|
|
Academic Article
|
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.
|
|
Academic Article
|
The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma.
|
|
Academic Article
|
Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit.
|
|
Academic Article
|
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
|
|
Academic Article
|
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma.
|
|
Academic Article
|
CTLA-4 Blockade Resistance after Relatlimab and Nivolumab.
|
|
Academic Article
|
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i).
|
|
Academic Article
|
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.
|
|
Academic Article
|
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.
|
|
Academic Article
|
Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma.
|
- Antibodies Monoclonal Humanized